Background: Concurrent radiochemotherapy has been established as a treatment standard for patients with inoperable non-small cell lung cancer (NSCLC) since the 1990s. There are potential synergistic effects between radiochemotherapy and immunotherapy. Thus, immune checkpoint inhibitors are increasingly used in patients with metastatic tumors. Objectives: What is the role of radioimmuntherapy in patients with stage III NSCLC? Materials and methods: A semistructured literature search was performed. Results: In this review, the established radiochemotherapy and the current data regarding potential synergisms between radiotherapy and immunotherapy are summarized. In this context, consolidation immunotherapy with durvalumab after chemoradiation offers a significant overall survival benefit as shown by the PACIFIC trial. Conclusion: Immunotherapy with durvalumab as consolidation therapy after concurrent radiochemotherapy represents a new paradigm for patients with stage III NSCLC. This could lead to a rearrangement of the current treatment algorithms for patients with stage III NSCLC, also with respect to surgery. While long-term data are still pending, further clinical studies are currently testing the role of immunotherapy in patients with stage III NSCLC.
|Translated title of the contribution||Locally advanced non-small cell lung cancer: radioimmunotherapy as new standard of care?|
|Number of pages||7|
|Publication status||Published - 01.11.2019|